Fluocinolone Acetonide Intravitreal Implant for the Treatment of Diabetic Macular Edema

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2013 Jun 6

PMID 23737661

Citations 6

Authors

Wyatt B Messenger

Robert M Beardsley

Christina J Flaxel

Affiliations

Soon will be listed here.

Abstract

Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fluocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fluocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fluocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fluocinolone acetonide intravitreal devices.

Citing Articles

Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.

Machado Soares R, Cunha Ferreira C, Fernandes J, Madeira C, Silva L, Saraiva E Clin Ophthalmol. 2024; 18:1057-1066.

PMID: 38646183 PMC: 11032137. DOI: 10.2147/OPTH.S382920.

New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy.

Park Y, Roh Y J Diabetes Res. 2016; 2016:1753584.

PMID: 26881240 PMC: 4736008. DOI: 10.1155/2016/1753584.

Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.

Jiang X, Lv H, Qiu W, Liu Z, Li X, Wang W Drug Des Devel Ther. 2015; 9:3043-50.

PMID: 26109847 PMC: 4472070. DOI: 10.2147/DDDT.S85529.

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant.

Bertelmann T, Schulze S Ophthalmol Ther. 2015; 4(1):51-8.

PMID: 25672501 PMC: 4470980. DOI: 10.1007/s40123-015-0028-0.

Advances in diabetic retinopathy.

Agarwal P, Jindal A, Saini V, Jindal S Indian J Endocrinol Metab. 2014; 18(6):772-7.

PMID: 25364670 PMC: 4192980. DOI: 10.4103/2230-8210.140225.

References

. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796-806. View

Do D, Nguyen Q, Boyer D, Schmidt-Erfurth U, Brown D, Vitti R . One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8):1658-65. DOI: 10.1016/j.ophtha.2012.02.010. View

Witmer A, Vrensen G, van Noorden C, Schlingemann R . Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003; 22(1):1-29. DOI: 10.1016/s1350-9462(02)00043-5. View

Campochiaro P, Hafiz G, Shah S, Bloom S, Brown D, Busquets M . Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010; 117(7):1393-9.e3. DOI: 10.1016/j.ophtha.2009.11.024. View

Tranos P, Wickremasinghe S, Stangos N, Topouzis F, Tsinopoulos I, Pavesio C . Macular edema. Surv Ophthalmol. 2004; 49(5):470-90. DOI: 10.1016/j.survophthal.2004.06.002. View

Klein R, Knudtson M, Lee K, Gangnon R, Klein B . The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116(3):497-503. PMC: 2693093. DOI: 10.1016/j.ophtha.2008.10.016. View

Faghihi H, Roohipoor R, Mohammadi S, Hojat-Jalali K, Mirshahi A, Lashay A . Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008; 18(6):941-8. DOI: 10.1177/112067210801800614. View

van der Reis M, La Heij E, de Jong-Hesse Y, Ringens P, Hendrikse F, Schouten J . A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011; 31(8):1449-69. DOI: 10.1097/IAE.0b013e3182278ab4. View

Flaxel C, Edwards A, Aiello L, Arrigg P, Beck R, Bressler N . Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina. 2010; 30(9):1488-95. PMC: 2975977. DOI: 10.1097/IAE.0b013e3181e7974f. View

10.

Kuppermann B, Blumenkranz M, Haller J, Williams G, Weinberg D, Chou C . Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125(3):309-17. DOI: 10.1001/archopht.125.3.309. View

11.

Ferris 3rd F, Patz A . Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984; 28 Suppl:452-61. DOI: 10.1016/0039-6257(84)90227-3. View

12.

Haller J, Kuppermann B, Blumenkranz M, Williams G, Weinberg D, Chou C . Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010; 128(3):289-96. DOI: 10.1001/archophthalmol.2010.21. View

13.

Ikeda T, Sato K, Katano T, Hayashi Y . Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol. 1999; 83(1):12-4. PMC: 1722776. DOI: 10.1136/bjo.83.1.12. View

14.

Gillies M, Sutter F, Simpson J, Larsson J, Ali H, Zhu M . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006; 113(9):1533-8. DOI: 10.1016/j.ophtha.2006.02.065. View

15.

Taylor S, Isa H, Joshi L, Lightman S . New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010; 224 Suppl 1:46-53. DOI: 10.1159/000318021. View

16.

Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N . Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009; 29(4):464-72. DOI: 10.1097/IAE.0b013e31819c632f. View

17.

Steijns D, Duijvesz D, Breedijk M, van der Heijden G . Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol. 2010; 88(4):389-93. DOI: 10.1111/j.1755-3768.2009.01657.x. View

18.

. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447-9, 1449.e1-10. PMC: 2748264. DOI: 10.1016/j.ophtha.2008.06.015. View

19.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

20.

Lewis H, Abrams G, Blumenkranz M, Campo R . Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992; 99(5):753-9. DOI: 10.1016/s0161-6420(92)31901-3. View